



DT07 Rec'd PCT/PTO 28 JAN 2003

Receipt
PCT

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Brossart, et al.) Group Art Unit 1645
Appl. No. : 10/019,513)
Filed : August 6, 2002)
For : PEPTIDE FOR TRIGGERING)
AN IMMUNE REACTION)
AGAINST TUMOR CELLS)
Examiner : Unknown)

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: United States Patent and Trademark Office, PO Box 2327, Arlington VA 22202, on

January 24, 2003

(Date)

Che S. Chereskin
Che Swyden Chereskin, Ph.D., Reg. No. 41,466

REQUEST FOR CORRECTED FILING RECEIPT

United States Patent and Trademark Office
P.O. Box 2327
Office of Initial Patent Examination
Customer Service Center
Arlington, VA 22202

RECEIVED
APR 30 2003
TECH CENTER 1600/2900

Dear Sir:

Applicants hereby request that the Official Filing Receipt, a copy of which is enclosed, be corrected to reflect the true title of PEPTIDE FOR TRIGGERING AN IMMUNE REACTION AGAINST TUMOR CELLS. Presently, the title incorrectly appears as Peptide from Antigen Muc-1 for Triggering an Immune Response to Tumor Cells.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated:

Jan. 24, 2003

By:

Che S. Chereskin

Che Swyden Chereskin, Ph.D.

Registration No. 41,466

Agent of Record

Customer No. 20,995

(949) 760-0404

WWELL52.001APC
Re: MRB/CSS



Commissioner for Patents
Washington, DC 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/019,513	08/06/2002	1645	1362	WWELL52.001APC		25	6

CONFIRMATION NO. 8680

20995
KNOBBE MARTENS OLSON & BEAR LLP
2040 MAIN STREET
FOURTEENTH FLOOR
IRVINE, CA 92614

FILING RECEIPT



OC00000009361574

Date Mailed: 01/13/2003

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Peter Brossart, Reutlingen, GERMANY;
Stefan Stevanovie, Tubingen, GERMANY;
Wolfram Brugger, Kusterdingen, GERMANY;
Lothar Kanz, Tubingen, GERMANY;
Hans-Georg Rammensee, Tubingen-Unterjessingen, GERMANY;

RECEIVED
APR 30 2003
TECH CENTER 1600/2900

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP00/02699 03/28/2000

Foreign Applications

GERMANY 199 17 195.5 04/16/1999

Projected Publication Date: None, application is not eligible for pre-grant publication

Non-Publication Request: No

Early Publication Request: No

Title

s/b Peptide for Triggering an Immune Reaction Against Tumor Cells

~~—Peptide from antigen muc-1 for triggering an immune response to tumor cells—~~

Preliminary Class

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).